

CorNotes

CVI SEMINAR SERIES

The next CVI-Research Division Seminar will be held on **Thursday, February 19, 2009 at 4:00 pm** in **The Van Kampen Conference Center, Building 110, Room 6274**. Our speaker will be:

Hossein Ardehali, M.D., Ph.D.
Assistant Professor of Medicine
Northwestern University Medical School
Chicago, IL

The title of Dr. Ardehali's seminar is:

"Novel Mitochondrial and Metabolic Mechanisms in Cardioprotection"

For further information about the CVI Seminar Series, contact Dr. Leanne Cribbs at x72817.

CVI JOURNAL CLUB

February 12
 February 26

Dr. Pluteanu
 Dr. Hoppensteadt

CVI Journal Club is held at 12:00 noon in the CVI Research Division Conference Room, Rm. 5215. For further information, contact Dr. Ken Byron at x72819.

CARDIOLOGY – CVI RESEARCH DIVISION BASIC SCIENCE SEMINAR

The Cardiology Division and the CVI Research Division are sponsoring a series of joint seminars by Loyola Faculty. The following seminar is scheduled at **7:30 am** in the **Van Kampen Conference Center**:

February 26 Dr. Jody Martin

For more information about this seminar series, contact Dr. Samarel at x72821.

RECENT PUBLICATIONS FROM THE CVI

Jeske WP, Walenga JM, Hoppensteadt D, McGeehan E, Kujawski M, Bakhos M. Pharmacodynamic differentiation of generic low molecular weight heparins. *Acta Colombiana de Cuidado Intensivo* 2008;8(1):10-15.

Fareed J, Walenga JM. A tribute to Professor Hans Klaus Breddin. *Semin Thromb Hemost* 2008;34(Suppl 1):5-6.

Hoppensteadt DA, Jeske W, Walenga JM, Bick RL, Fareed J. The anti-inflammatory effects of argatroban can be differentiated from other direct thrombin inhibitors: experimental and clinical observations. *Semin Thromb Hemost* 2008;34(Suppl 1):97-102.

Adiguzel C, Iqbal O, Cunanan J, Jeske W, Hoppensteadt D, Walenga JM, Fareed J. Potency adjusted generic versions of argatroban can be differentiated from branded argatroban in thrombin generation and platelet activation assays. *Semin Thromb Hemost* 2008;34(Suppl 1):108-118.

Fareed J, Walenga JM, Jeske WP, Hoppensteadt D, Prechel M, Iqbal O, Adiguzel C, Clark M, Litinas E, Cunanan J, Linhardt R, Harenberg J. Biological profile of the hyper/oversulfated chondroitin sulfate contaminant isolated from recalled heparin. *Semin Thromb Hemost* 2008;34(Suppl 1):119-127.

Fareed J, Walenga JM, Hoppensteadt DA, Bick RL, Messmore HL. Dr. Eberhard F. Mammen remembered. A great clinician-scientist, mentor, and friend. *Semin Thromb Hemost* 2008;34(Suppl 1):128-129.

Kawano H, Toyoda K, Miyata S, Yamamoto H, Okamoto A, Kakutani I, Walenga JM, Naritomi H, Minematsu K. Heparin-induced thrombocytopenia: a serious complication of heparin therapy for acute stroke. *Cerebrovasc Dis* 2008;26:641-649.

Hoppensteadt DA, Walenga JM. The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia. In: Bick RL, Baker WF (ed): *Hematology/Oncology Clinics of North America. Antiphospholipid Thrombosis Syndromes*. Elsevier Saunders, Philadelphia, PA, 2008;22(1):1-18.

Jeske WP, Walenga JM, Fareed J. Differentiating between the low-molecular-weight heparins used for venous thromboembolism treatment and prophylaxis. In: Merli G (ed): *Thrombosis Clinic*. Excerpta Medica/Elsevier, Bridgewater, NJ, 2008;2(3):8-21.

Wang YG, Ji X, Pabbidi M, Samarel AM, Lipsius SL. Laminin acts via focal adhesion kinase/phosphatidylinositol-3' kinase/protein kinase B to downregulate β_1 -adrenergic receptor signalling in cat atrial myocytes. *J. Physiol.*, 587.3:541-550, 2009.